Home › Hepatitis C › NCT06367465

Feasibility and Acceptability of HCV Treatment in Pregnancy

Feasibility and Acceptability of Early Linkage to HCV Treatment in Pregnancy Feasibility and Acceptability of Early Linkage to HCV Treatment in Pregnancy

Who can join

Ages 18 and older · Women

Inclusion Criteria:

* Female patients ≥ 18 years old, pregnant at the time of study intake, diagnosed with hepatitis c virus infection and a history of past or current drug use.

Exclusion Criteria:

\-

About the study

Pregnant adults over the age of 18 who are seen in the Washington University obstetrics and gynecology, maternal fetal medicine or infectious diseases clinic or admitted to BJH with hepatitis C virus infection who have a history of past or current drug use

Participant Duration: Approximately 1 year.

Aims:

Aim 1 - Evaluate adherence and treatment completion rates when glecaprevir-pibrentasvir is started during pregnancy for women who use drugs.

Aim 2 - Evaluate patient experience with hepatitis C virus treatment during pregnancy.

What is being tested

• Glecaprevir-pibrentasvir (drug)

Sponsor: Washington University School of Medicine · Participants: 50 · Started: Feb 1, 2024

Contact the study team

• Tracey Bach, MBA · Phone: 314-273-6075

Official record on ClinicalTrials.gov — NCT06367465

Locations in the U.S.

Conditions

• Hepatitis C
• Tumors and Pregnancy

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.